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Objective: This study aimed at ascertaining the relationship between obesity and preeclampsia and the role of fibrinogen 
and C-reactive protein (CRP).
study design: This was a case-control study involving 200 pregnant women, 100 of whom were healthy pregnant women, 
and 100 preeclamptic women, matched for age, parity, and gestational age. Information about their sociodemographic 
characteristics was obtained and body mass index (BMI) calculated using their height and weight at recruitment. Their plasma 
fibrinogen and CRP levels were assayed using enzyme‑linked immunosorbent assay (ELISA) technique. All data collected 
were subjected to statistical analysis using Epi Info.
Results: The mean (±SD) age of subjects was 31.1 ± 4.51 years. The preeclamptic subjects were found to have higher BMI 
(30.04 ± 6.06 kg/m2) compared to the normotensive pregnant women (28.08 ± 2.97 kg/m2). However, this was not statistically 
significant. Using mean arterial blood pressure as an indicator of disease severity, with a cut‑off of 125 mmHg, it was found that 
severe preeclamptics had higher BMI (30.18 ± 6.49 kg/m2) compared to women with mild form of the disease (29.83 ± 5.48 kg/m2) 
but this difference was not statistically significant (P = 0.2131). There was also statistically significant association between BMI 
and high-sensitivity C-reactive protein (hsCRP) (P = 0.0000), and between BMI and plasma fibrinogen levels (P = 0.0000).
Conclusion: It can thus be inferred from this study that obesity elicits inflammatory response which might predispose to the 
development of preeclampsia. Lifestyle modifications such as dietary control, exercise, and pre‑pregnancy weight reduction 
may help in reducing the incidence of preeclampsia.
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Introduction
Preeclampsia is a multisystemic disorder characterized by 
hypertension in previously normotensive pregnant woman 
with associated proteinuria, occurring after 20 weeks 
gestation.[1] It is a common cardiovascular complication that 
may arise in pregnancy, and poses danger to both mother 
and baby. Its etiology is unknown but many postulations 
have been made overtime. The worldwide prevalence of 
preeclampsia is 2–8%.[2]
Obesity is defined as body mass index (BMI) of 30 kg/m2 
or more. The prevalence of obesity varies from country to 
country. According to the World Health Organization (WHO), 
the prevalence of overweight and obese women combined 
(BMI of ≥25 kg/m2) is 77% in the United States, 73% in Mexico, 
37% in France, 32% in China, and 18% in India.[3] In Nigeria, 
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the prevalence of overweight and obese women has been 
estimated to be 20.3–35.1% and 8.1–22.2% respectively.[4] 
Obesity has been found to be a risk factor in many medical 
conditions, of which cardiovascular disease is one.[5,6]
Several studies conducted have identified preeclampsia 
as an inflammatory condition. A number of inflammatory 
markers, e.g., C-reactive protein (CRP), IL-6, fibrinogen, 
TNFα, etc., have been found to be elevated in patients with 
preeclampsia.[7-9] More recently, an association has been 
established between obesity and levels of inflammatory 
markers, suggesting that obesity is an inflammatory disease 
or predisposes to various adverse medical conditions by 
causing inflammation.[6,10-12] It is known that obesity is 
associated with elevated serum leptin level. In a study by 
El-Mekhzangy et al., it was found that serum leptin level 
is significantly higher in preeclampsia when compared 
with normotensive pregnant women and this is thought 
to be a contributory factor to the endothelial dysfunction 
involved in the pathogenesis of preeclampsia.[13] If this be 
the case, then is there any association between obesity and 
preeclampsia?
In some studies, most of which were conducted in developed 
countries, it has been established that there is a three-fold 
increase in the risk of an obese pregnant woman developing 
preeclampsia.[14] It therefore follows that there is a possibility 
that obesity elicits chronic inflammation in the vascular 
system and this might serve as a trigger for the development 
of preeclampsia.
Researches are still on-going worldwide to establish the 
cause of preeclampsia and to identify modifiable factors 
that may be adjusted to prevent its occurrence. The most 
popular of these has remained the use of low dose aspirin, 
which has been found to be useful in minimizing the risk 
of development of preeclampsia if commenced early in 
pregnancy.
Obesity, as we know is a modifiable condition. So, if we are 
able to establish a clear-cut association between obesity and 
preeclampsia, it might be easier for us to institute strategies 
to prevent its occurrence, considering the huge burden the 




•  To assess if there is a relationship between obesity, 






Conducted at the Lagos University Teaching Hospital, 
Surulere, Lagos following ethical approval by the Health 
Research and Ethics Committee (HREC).
Study population
This comprised 100 normotensive pregnant women and 






•  Women with  chronic medical  disorders  such  as  renal 
disease, diabetes mellitus, human immunodeficiency 
virus infection, or other symptomatic infections
•  Those with multiple gestations
•  Those transfused with blood in the last 1 month
•  Those who have had steroid in the last 24 hours.
Data/sample collection
Information about their sociodemographic characteristics 
was obtained. BMI calculated using their height and weight 
at recruitment. Their plasma fibrinogen and CRP levels were 
assayed using enzyme-linked immunosorbent assay (ELISA) 
technique.
Data management
The data collected was analyzed using the Epi Info. Chi-square 
and Kruskal-Wallis were used to test for statistical significance 
where applicable. A P value <0.05 was considered to be 
statistically significant.
Results
Clinical profile of patients
The mean age ± S.D. of subjects was 31.1 ± 4. 46 years for 
the preeclamptic women and 31.1 ± 4. Fifty eight years for 
the control group (P = 0.9345) [Table 1].
Association between obesity and preeclampsia
Preeclamptics have higher BMI (30.04 ± 6.06 kg/m2) than 
normotensive pregnant women (28.08 ± 2.97 kg/m2). 
However, this was not statistically significant. Using mean 
arterial blood pressure (MAP) as an indicator of disease 
severity, with a cut off of 125 mmHg, it was found that severe 
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preeclamptics had higher BMI (30.18 ± 6.49 kg/m2) compared 
to women with mild form of the disease (29.83 ± 5.48 kg/m2), 
P = 0.2131 [Figure 1].
Association between obesity and markers of 
inflammation
There was statistically significant association between 
BMI and hsCRP (P = 0.0000). There was statistically 
significant association BMI and plasma fibrinogen levels 
(P = 0.0000).
Levels of inflammatory markers in preeclamptic and 
normotensive pregnant women
The hsCRP level is higher in preeclamptics compared to 
normotensive pregnant women, median values of 5.70 mg/L 
and 4.35 mg/L respectively (P = 0.0453). The hsCRP level is 
higher in women with severe preeclampsia compared to those 
with mild form of the disease, median values of 5.80 mg/L 
and 5.60 mg/L respectively [Table 1]. A large proportion of 
subjects with high levels of hsCRP and plasma fibrinogen are 
overweight and obese [Figures 2 and 3].
Plasma fibrinogen level is higher in preeclamptics compared 
to normotensive pregnant women, median values of 
97.7 mg/dl and 52.9 mg/dl respectively (P = 0.0021). 
Plasma fibrinogen level is higher in women with severe 
preeclampsia compared to those with mild form of the 
disease, median values of 86.0 mg/dl and 101.2 mg/dl 
respectively.
Discussion
Preeclamptic women in this study were found to have higher 
BMI. Similar observation was made in Southeastern Nigeria.[15] 
This finding is not surprising as obesity for a long time has 
been linked with various chronic diseases such as metabolic 
syndrome, cardiovascular diseases, diabetes, hypertension, 
non-alcoholic liver cirrhosis, and some cancers.[6]
Women with severe preeclampsia were also observed to 
be weightier than those with mild form of the disease. 
Considering the fact that obesity was adjudged to be a 
possible inflammatory trigger in a number of studies;[8,12,15] it 
therefore follows that the difference in BMI based on disease 
severity might be related to the degree of inflammation, 
thereby buttressing the fact that obesity is a possible trigger 
of inflammation. This assumption is further supported by the 
finding of higher levels of the inflammatory markers, CRP, 
and plasma fibrinogen in women with severe preeclampsia 
compared to women with mild form of the disease in this 
study.
There is a greater expression of inflammatory markers 
in preeclamptics compared to normotensive pregnant 
women, as hsCRP and fibrinogen levels were found to be 
Table 1: Distribution of subjects by age and level of inflammatory markers
Mild pre‑eclampsia n=37 Severe pre‑eclampsia n=63 Control n=100 P
Maternal age (years) 32 (19-42) 31 (22-40) 0.9345
Plasma fibrinogen (mg/dl) 97.7 (20.1-623.9) 52.9 (20.8-848.5) 0.0021
Plasma fibrinogen (mg/dl) 86.0 (20.1-623.9) 101.2 (24.5-306.6) 0.5551
hsCRP (mg/L) 5.70 (-0.2-12.0) 4.35 (0.0-10.6) 0.0453
hsCRP (mg/L) 5.60 (0.1-12.0) 5.80 (‒0.2-11.3) 0.9118








































































































































Figure 1: Association between body mass index (BMI) and pre-eclamptic 
and normotensive pregnant women
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significantly higher in the preeclamptics. Similar findings 
have been reported previously in several other studies.[15-17] 
Statistically, significant associations were found between 
obesity and hsCRP and plasma fibrinogen levels. Veigas 
et al. also reported a strong association between BMI, 
waist circumference and fat mass, and CRP and fibrinogen 
levels.[18] This further buttresses the fact that obesity is a 
trigger of inflammation.
In obesity, it has been found that the production of IL-6 
in human adipose tissue increases and it may induce CRP 
synthesis in the liver, which in turn may promote onset 
of cardiovascular complications and insulin resistance.[11] 
Obesity may thus be considered a subclinical inflammatory 
condition.
Considering the prevalence of obesity worldwide, it becomes 
important to employ strategies to minimize obesity in the 
pre-pregnancy period with the hope of reducing the incidence 
and/or the severity of preeclampsia. Strategies that may 
be employed to reduce excess weight gain include dietary 
modifications and regular exercises. This calls for persistent 
health education of our women on the risk associated with 
obesity even in pregnancy and the need to embark on 
pre-pregnancy weight reduction in order to avert complications 
like preeclampsia and other forms hypertensive disorders in 
pregnancy. By so doing we may be able to reduce maternal 
mortality rate as preeclampsia till date has remained one of 
the leading causes of maternal deaths and fetal wastages.
Conclusion
It can thus be inferred from this study that obesity elicits 
inflammatory response which might predispose to the 
development of preeclampsia. Lifestyle modifications such as 
dietary control, exercise, and pre-pregnancy weight reduction 
may help in reducing the incidence of preeclampsia.
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Figure 3: Distribution of subjects by BMI and fibrinogen levels
